UPDATE: Pacira Pharma (PCRX) Tops Q3 EPS by 23c, Revenues Beat; Boosts FY18 Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to UPDATE: Pacira Pharma (PCRX) Tops Q3 EPS by 23c, Revenues Beat; Boosts FY18 Revenue Outlook

Pacira Pharmaceuticals (PCRX) PT Raised to $46 at Mizuho Securities Following 3Q

November 5, 2018 7:16 AM EST

Mizuho Securities analyst Irina Koffler raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $46.00 (from $43.00) while maintaining a Neutral rating following the company's 3Q earnings report. Mizuho Securities raised 2018 Exparel sales to $331.8M (from $321.2M) and 2019 estimates to $396.5M (from $376.8M prior); both above... More

Pacira Pharmaceuticals (PCRX) PT Raised to $60 at RBC Capital

November 2, 2018 7:14 AM EDT

RBC Capital analyst Randall Stanicky raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $60.00 (from $55.00) while maintaining a Outperform rating.

... More

Pacira Pharmaceuticals (PCRX) PT Raised to $55 at Piper Jaffray

November 1, 2018 1:13 PM EDT

Piper Jaffray analyst David Amsellem raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $55.00 (from $51.00) while maintaining a Overweight rating.

Amsellem cited a clear uptick in Exparel sales growth.

... More